In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.
UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles—tiny particles naturally released by nearly all types of cells that help them communicate with one another.
Their preclinical study found that vesicles produced by certain types of pluripotent stem cells (PSCs) can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model. The research was inspired in part by a feature of pregnancy, which means that the mother’s immune system generally tolerates a developing embryo, even though it carries genetic material from the father that the maternal immune system could recognize as foreign. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.
Song Li, PhD, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center, is senior and corresponding author of the team’s published paper in Nature Nanotechnology, titled “Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy.”
Embryonic development is characterized by “remarkable immune tolerance,” the authors noted, “… yet whether this property extends to pluripotent stem cell-derived extracellular vesicles (EVs) has remained unclear.” Li added, “Nature has designed something amazing. If we can better understand how an embryo avoids rejection by the mother’s immune system, it could be very useful for a lot of immune-related diseases.”
For their study the team investigated whether extracellular vesicles released by pluripotent stem cells—which share characteristics with cells found in early embryonic development—might also possess immune-regulating properties. The researchers compared vesicles from embryonic stem cells (ESCs) and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells (MSCs), which have been widely studied for their ability to regulate inflammation. “Extracellular vesicles (EVs) secreted by adult stem cells, particularly mesenchymal stem cells (MSCs), have been extensively investigated for their regenerative potential across a wide range of pathological conditions,” the team pointed out.
In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells (Tregs), specialized immune cells that help prevent the immune system from attacking the body’s own tissues. “… we show that EVs from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells, outperform mesenchymal stem cell-derived EVs in suppressing proinflammatory cytokine secretion, reducing T cell activation and inducing regulatory T cells,” they stated.
Further analysis showed that the vesicles carry distinctive proteins, lipids, and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells. “… PSC EVs display distinct molecular signatures, containing unique proteins and microRNAs absent from mesenchymal stem cell-derived EVs, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family,” the investigators continued.
To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.
Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days. “Soluble EVs are cleared rapidly from subcutaneous tissue, and therefore, we developed an injectable hydrogel composed of hyaluronic acid (HA) and Pluronic F127 that transitions from a solution to a gel state at body temperature,” they explained. “Both polymers are widely used in biomedical formulations, which further supports the translational potential of this platform.”
The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas. The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls.
At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free. Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals. “Delivered via a biomaterial scaffold, two local injections of induced PSC EVs significantly improved diabetes-free survival in an antigen-specific type 1 diabetes model, increasing regulatory T cell populations in draining lymph nodes, as well as inducing systemic immune modulation and preserving β-cell mass,” the scientists stated.
“One thing that surprised us was that a local injection could provide protection throughout the body,” said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. “That’s the beauty of this approach.”
The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles. Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. “Suspension culture allows PSCs to grow as floating aggregates and maintain pluripotency without differentiation into embryoid bodies,” they explained. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles. Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.
The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people. Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.
“In the early stages, you still have some pancreatic cells left,” Li said. “If you can regulate the immune cells, you may be able to keep the remaining cells functional.” In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.
The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness, and whether the treatment could weaken the body’s defenses against infection.
Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection. Acknowledging questions that still remain to be addressed, the authors concluded, “These findings establish PSC EVs as a scalable immunomodulatory platform for autoimmune disease and for immune tolerance in cell therapy.”

